Application of dha@zif-8 in treatment of experimental cerebral malaria

Abstract

The disclosure belongs to the technical field of biomedicine, and specifically relates to an application of DHA@ZIF-8 in the treatment of experimental cerebral malaria. In the disclosure, an experimental cerebral malaria model is first established. Subsequently, DHA@ZIF-8 is used for treatment in the model, and the therapeutic efficacy of the nanodrug against experimental cerebral malaria is evaluated using behavioral, pathological, and molecular biological techniques. In the disclosure, the use of ZIF-8 as a carrier achieves the effect of slowly releasing the drug, prolonging the duration of action of the drug in vivo, so as to more effectively kill Plasmodium. Compared with natural administration, this approach extends the duration of action of DHA.

Dependencies are inferred from the claim text.